Pushing the limits of treatment for hepatocellular carcinoma

Abstract

Purpose of review We review existing and newer strategies for treatment and surveillance of hepatocellular carcinoma (HCC) both pre and postliver transplantation. Summary HCC is rising in incidence and patients are often diagnosed at later stages. Consequently, there is a need for treatment strategies which include collaboration of multiple specialties. Combinations of locoregional, systemic, and surgical therapies are yielding better postliver transplantation (post-LT) outcomes for patients with HCC than previously seen. Tumor biology (tumor size, number, location, serum markers, response to therapy) can help identify patients who are at high risk for HCC recurrence posttransplantation and may expand transplant eligibility for some patients.

Outcome of Atezolizumab Plus Bevacizumab Combination Therapy in High-Risk Patients with Advanced Hepatocellular Carcinoma

“…Both studies reported that the combination of ATE + BEV and radiotherapy showed tolerable and manageable toxicity. Jones-Pauely et al suggested that combination of systemic and locoregional therapy might provide patients with large tumor burden opportunity from effective tumor control to downstaging [25]. However, this alone cannot explain all the success which occurred in the high-risk group because more than half of the highrisk group in this study had extrahepatic metastases that were not covered by radiation therapy.…”